All In Biotech

Drug Trial Radar · NCT07529535

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

An Open-label, Multicenter, Dose-escalationStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

16

Actual

Start

Jun 5, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label, dose-escalation plus rollover and cohort expansion Phase I/II clinical trial conducted in patients with advanced solid tumors, including esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma. It aims to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ALK-N001 for injection as monotherapy in the treatment of advanced solid tumors such as esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma.

Conditions

  • Advance Solid Tumors

Interventions

  • ALK-N001 for InjectionDrug

    The drug is administered via intravenous infusion at a constant rate . The primary dosing schedule was every 2 weeks (Q2W) in a 28-day cycle, while an every 3 weeks (Q3W) schedule with a 21-day cycle was also explored.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity(DLT)Time frame: Through study completion, an average of 2 years
  2. Incidence of Adverse Events (AEs)Time frame: Through study completion, an average of 2 years
  3. Incidence of Serious Adverse Events (SAEs)Time frame: Through study completion, an average of 2 years
  4. Incidence of AEs Leading to Permanent Treatment DiscontinuationTime frame: Through study completion, an average of 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Zhongshan Hospital, Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.